Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE
ChemMedChem · 27.03.2026 · 21 (6)
DOI: 10.1002/cmdc.202501084 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 26.03.2026. Verfasst von Taopeng Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Anhui University of Chinese Medicine, Hefei, China. Hauptthemen laut MEDLINE: Vancomycin, beta-Lactams. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Province Science Foundation for Youths, Shanghai Post-doctoral Excellence Program.
Abstract (Originalsprache)
Antimicrobial resistance (AMR) poses a significant global public health challenge. Vancomycin and β‐lactam antibiotics, critical for treating multidrug‐resistant (MDR) bacterial infections, are hindered by resistant strains such as vancomycin‐resistant Enterococci (VRE) and vancomycin‐intermediate Staphylococcus aureus , as well as β‐lactamase‐mediated resistance. This article leverages the complementary mechanisms of these antibiotics, which target bacterial cell wall synthesis, to develop vancomycin‐β‐lactam hybrids as a novel strategy against AMR. Through chemical modification, β‐lactam fragments were introduced at the carboxyl (C), resorcinol (R), and amine (N) termini of vancomycin, yielding multiple hybrid series. In vitro activity assays revealed that C‐terminal modified vancomycin–penicillin hybrids exhibited superior efficacy, with compound 6a–6g reducing the minimum inhibitory concentration against strains such as VREs by 512–1024‐fold compared to vancomycin, achieving activity comparable to oritavancin in certain strains. In vitro safety evaluations demonstrated low cytotoxicity of 6a against human kidney (HK2) and embryonic kidney (HEK293) cell lines. These findings establish 6a as a promising drug candidate, offering a novel therapeutic option for MDR infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anhui University of Chinese Medicine, Hefei, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
ORCID-Profile: Chengtao Feng, Xiaowen Wang, Dongliang Guan
Förderung
- National Natural Science Foundation of China
- Shandong Province Science Foundation for Youths
- Shanghai Post-doctoral Excellence Program
- Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation
- Key R&D Program of Shandong Province
Zitieren
APA
Chang, T., Li, F., Feng, C., Wang, X., & Guan, D. (2026). Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE. ChemMedChem, 21(6). https://doi.org/10.1002/cmdc.202501084
Vancouver
Chang T, Li F, Feng C, Wang X, Guan D. Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE. ChemMedChem. 2026;21(6). doi:10.1002/cmdc.202501084
BibTeX
@article{Chang2026,
author = {Chang, Taopeng and Li, Fang and Feng, Chengtao and Wang, Xiaowen and Guan, Dongliang},
title = {Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {6},
doi = {10.1002/cmdc.202501084}
}
EUVIMED